Atara biotherapeutics and pierre fabre laboratories announce publication of phase 3 allele tab-cel® data in the lancet oncology

Thousand oaks, calif. & castres, france--(business wire)---- $atra #cart--atara biotherapeutics, inc. (nasdaq: atra), a leader in t-cell immunotherapy, leveraging its novel allogeneic epstein-barr virus (ebv) t-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, and pierre fabre laboratories, a global player in oncology and responsible for worldwide commercialization of tabelecleucel (tab-cel® or ebvallo™), today announced that data from the pivotal phase 3 allel.
ATRA Ratings Summary
ATRA Quant Ranking